Core Viewpoint - Anhui Huaheng Biological Technology Co., Ltd. plans to issue H shares and list on the Hong Kong Stock Exchange to enhance its global development strategy, brand influence, and core competitiveness [1][2]. Meeting Details - The 18th meeting of the 4th Supervisory Board was held on September 4, 2025, with all three supervisors present, complying with relevant laws and regulations [1]. H Share Issuance Proposal - The Supervisory Board approved the proposal for issuing H shares and listing on the Hong Kong Stock Exchange, aiming to optimize capital structure and broaden financing channels [2][3]. - The H shares will be ordinary shares with a par value of RMB 1, issued in foreign currency [2]. Issuance and Listing Plan - The issuance will include both public offerings in Hong Kong and international placements, with the total number of H shares not exceeding 15% of the company's total share capital post-issuance [3][4]. - The final issuance price will be determined based on market conditions and investor demand [4]. Fund Utilization Plan - The funds raised from the H share issuance will be used for global expansion, new product development, capacity upgrades, and general corporate purposes [8][9]. Transition to Overseas Listed Company - Following the H share issuance, the company will transition to an overseas listed public company, listed on both the Shanghai Stock Exchange and the Hong Kong Stock Exchange [9]. Audit and Professional Services - The Supervisory Board approved the appointment of Yongcheng (Hong Kong) CPA Limited as the auditing firm for the H share issuance [10]. Governance Changes - The company plans to abolish the Supervisory Board and amend its Articles of Association to align with the latest legal requirements and improve governance structure [11].

Group 1 - The company plans to appoint RSM Hong Kong as the auditing firm for its H-share issuance and listing on the Hong Kong Stock Exchange, pending approval from the shareholders' meeting [1][2] - RSM Hong Kong was established on May 14, 2008, and is registered as a public interest entity auditor under the Hong Kong Accounting and Financial Reporting Ordinance, providing diverse services to clients [1][2] - The audit fees will be determined based on the company's business scale, work requirements, industry complexity, and the number of audit personnel involved, with management authorized to negotiate the final fees [2] Group 2 - The audit committee has reviewed and approved the appointment of RSM Hong Kong, confirming its professional capability and independence for the H-share issuance and listing [2] - The board of directors voted 9 in favor to appoint RSM Hong Kong as the auditing firm and to submit the proposal for shareholder approval [2] - The appointment of the auditing firm will take effect upon approval at the company's first extraordinary shareholders' meeting in 2025 [3]

Core Viewpoint - The company is moving forward with the issuance of H shares and plans to list on the Hong Kong Stock Exchange, which is seen as beneficial for its global development strategy and enhancing its international brand image [1][2]. Group 1: H Share Issuance and Listing - The independent directors unanimously support the proposal for the company to issue H shares and list on the Hong Kong Stock Exchange, believing it will aid in the company's global strategy and enhance its competitiveness [1]. - The proposed plan for the H share issuance complies with relevant laws and regulations, ensuring it does not harm the interests of the company or its shareholders [2]. - The fundraising plan associated with the H share issuance aligns with the company's development needs and global strategy, benefiting all shareholders [2]. Group 2: Profit Distribution and Insurance - The profit distribution plan prior to the H share issuance has been deemed fair to existing and future shareholders, with no adverse effects on their rights [2]. - The proposal to purchase liability insurance for directors and senior management is in accordance with legal requirements and market practices, ensuring no improper benefits are conferred [3]. - The independent directors support the hiring of a reputable auditing firm, which possesses the necessary experience and independence for the H share issuance project [3]. Group 3: Previous Fundraising Report - The report on the usage of previously raised funds has been reviewed and found to comply with regulatory requirements, accurately reflecting the company's financial activities up to December 31, 2024 [4].